Leerink Partners Sticks to Its Buy Rating for Universal Health (UHS)
Confident Investing Starts Here:
Mayo covers the Healthcare sector, focusing on stocks such as Humana, Pediatrix Medical Group, and Tenet Healthcare. According to TipRanks, Mayo has an average return of 2.9% and a 49.75% success rate on recommended stocks.
In addition to Leerink Partners, Universal Health also received a Buy from Wells Fargo's Stephen Baxter in a report issued on May 29. However, yesterday, Morgan Stanley maintained a Hold rating on Universal Health (NYSE: UHS).
Based on Universal Health's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $4.1 billion and a net profit of $316.68 million. In comparison, last year the company earned a revenue of $3.84 billion and had a net profit of $261.83 million
Based on the recent corporate insider activity of 51 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of UHS in relation to earlier this year. Last month, Maria Singer Ruderman, a Director at UHS sold 1,097.00 shares for a total of $210,042.59.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
Centene's (NYSE:CNC) Q2 Sales Beat Estimates But Stock Drops 12.2%
Health coverage company Centene (NYSE:CNC) reported Q2 CY2025 results topping the market's revenue expectations , with sales up 22.4% year on year to $48.74 billion. Its non-GAAP loss of $0.16 per share was significantly below analysts' consensus estimates. Is now the time to buy Centene? Find out in our full research report. Centene (CNC) Q2 CY2025 Highlights: Lower payments from the government, higher medical costs, more expensive care for Medicaid members Revenue: $48.74 billion vs analyst estimates of $43.67 billion (22.4% year-on-year growth, 11.6% beat) Adjusted EPS: -$0.16 vs analyst estimates of $0.23 (significant miss) Adjusted EBITDA: -$282 million vs analyst estimates of $91.23 million (-0.6% margin, significant miss) Operating Margin: -0.9%, down from 3.1% in the same quarter last year Free Cash Flow Margin: 3.2%, down from 5% in the same quarter last year Customers: 28 million, up from 27.94 million in the previous quarter Market Capitalization: $13.32 billion "We are disappointed by our second quarter results, but we have a clear understanding of the trends that have impacted our performance, and are working with urgency and focus to restore our earnings trajectory," said Chief Executive Officer of Centene, Sarah M. London. Company Overview Serving nearly 1 in 15 Americans through its government healthcare programs, Centene (NYSE:CNC) is a healthcare company that manages government-sponsored health insurance programs like Medicaid and Medicare for low-income and complex-needs populations. Revenue Growth Examining a company's long-term performance can provide clues about its quality. Any business can put up a good quarter or two, but the best consistently grow over the long haul. Luckily, Centene's sales grew at a solid 14.2% compounded annual growth rate over the last five years. Its growth beat the average healthcare company and shows its offerings resonate with customers, a helpful starting point for our analysis. Long-term growth is the most important, but within healthcare, a half-decade historical view may miss new innovations or demand cycles. Centene's annualized revenue growth of 9.8% over the last two years is below its five-year trend, but we still think the results were respectable. Centene also reports its number of customers, which reached 28 million in the latest quarter. Over the last two years, Centene's customer base averaged 1.2% year-on-year growth. Because this number is lower than its revenue growth, we can see the average customer spent more money each year on the company's products and services. This quarter, Centene reported robust year-on-year revenue growth of 22.4%, and its $48.74 billion of revenue topped Wall Street estimates by 11.6%. Looking ahead, sell-side analysts expect revenue to remain flat over the next 12 months, a deceleration versus the last two years. This projection doesn't excite us and suggests its products and services will see some demand headwinds. At least the company is tracking well in other measures of financial health. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. Operating Margin Centene's operating margin might fluctuated slightly over the last 12 months but has generally stayed the same, averaging 1.5% over the last five years. This profitability was lousy for a healthcare business and caused by its suboptimal cost structure. Analyzing the trend in its profitability, Centene's operating margin might fluctuated slightly but has generally stayed the same over the last five years. This raises questions about the company's expense base because its revenue growth should have given it leverage on its fixed costs, resulting in better economies of scale and profitability. This quarter, Centene's breakeven margin was down 4 percentage points year on year. This contraction shows it was less efficient because its expenses grew faster than its revenue. Earnings Per Share Revenue trends explain a company's historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth – for example, a company could inflate its sales through excessive spending on advertising and promotions. Centene's flat EPS over the last five years was below its 14.2% annualized revenue growth. However, its operating margin didn't change during this time, telling us that non-fundamental factors such as interest and taxes affected its ultimate earnings. In Q2, Centene reported EPS at negative $0.16, down from $2.42 in the same quarter last year. This print missed analysts' estimates. Over the next 12 months, Wall Street expects Centene's full-year EPS of $5.16 to shrink by 24.8%. Key Takeaways from Centene's Q2 Results We liked that Centene beat analysts' revenue expectations this quarter. On the other hand, EPS missed significantly due to lower payments from the government, higher medical costs, more expensive care for Medicaid members. Management called the results "disappointing" and are addressing the issues in the business. Shares traded down 12.2% to $23.51 immediately following the results. Is Centene an attractive investment opportunity at the current price? If you're making that decision, you should consider the bigger picture of valuation, business qualities, as well as the latest earnings. We cover that in our actionable full research report which you can read here, it's free. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Kellanova Declares Regular Dividend of $0.58 per Share for Third Quarter
CHICAGO, July 25, 2025 /PRNewswire/ -- Kellanova (NYSE: K) today announced that its Board of Directors declared a dividend of $0.58 per share on the common stock of Kellanova, payable on September 15, 2025, to shareowners of record at the close of business on is September 2, 2025. The ex-dividend date is September 2, 2025. This is the 403rd dividend that Kellanova has paid to owners of common stock since 1925 and is a one cent increase from its previous quarterly rate. About Kellanova Kellanova (NYSE: K) is a leader in global snacking, international cereal and noodles, and North America frozen foods with a legacy stretching back more than 100 years. Powered by differentiated brands including Pringles®, Cheez-It®, Pop-Tarts®, Kellogg's ® Rice Krispies Treats®, RXBAR®, Eggo®, MorningStar Farms®, Special K®, Coco Pops®, and more, Kellanova's vision is to become the world's best-performing snacks-led powerhouse, unleashing the full potential of our differentiated brands and our passionate people. Our net sales for 2024 were approximately $13 billion. At Kellanova, our purpose is to create better days and ensure everyone has a seat at the table through our trusted food brands. We are committed to promoting sustainable and equitable food access by tackling the crossroads of hunger, sustainability, wellbeing, and equity, diversity & inclusion. Our goal is to create Better Days for 4 billion people by the end of 2030 (from a 2015 baseline). For more detailed information about our commitments, our approach to achieving these goals, and methodology, please visit our website at [K-DIV] [K-FIN] View original content to download multimedia: SOURCE Kellanova IR Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
an hour ago
- Business Wire
Securities Fraud Investigation Into Barnes & Noble Education, Inc. (BNED) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
LOS ANGELES--(BUSINESS WIRE)-- Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Barnes & Noble Education, Inc. ('Barnes & Noble' or the 'Company') (NYSE: BNED) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON BARNES & NOBLE EDUCATION, INC. (BNED), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. What Happened? On July 18, 2025, Barnes & Noble disclosed that '[c]ertain information regarding the recording of cost of digital sales was brought to the attention of management' and that, as a result, 'management believes that the Company may have a potential overstatement of up to $23.0 million in the aggregate to its accounts receivable balance as of its May 3, 2025 fiscal year-end.' On this news, Barnes & Noble's stock price fell $2.36, or 21%, to close at $8.87 per share on July 21, 2025, thereby injuring investors. Contact Us To Participate or Learn More: If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us. Charles Linehan, Esq. Glancy Prongay & Murray LLP 1925 Century Park East, Suite 2100 Los Angeles California 90067 Email: shareholders@ Telephone: 310-201-9150 (Toll-Free: 888-773-9224) Visit our website at Follow us for updates on LinkedIn, Twitter, or Facebook. Whistleblower Notice Persons with non-public information regarding Barnes & Noble should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program. Under the program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Charles H. Linehan at 310-201-9150 or 888-773-9224 or email shareholders@ About Glancy Prongay & Murray LLP Glancy Prongay & Murray LLP ('GPM') is a premier law firm representing investors and consumers in securities litigation and other complex class action litigation. GPM has been consistently ranked in the Top 50 Securities Class Action Settlements by ISS Securities Class Action Services. In 2018, GPM was ranked a top five law firm in number of securities class action settlements, and a top six law firm for total dollar size of settlements. With four offices across the country, GPM's nearly 40 attorneys have won groundbreaking rulings and recovered billions of dollars for investors and consumers in securities, antitrust, consumer, and employment class actions. GPM's lawyers have handled cases covering a wide spectrum of corporate misconduct and relating to nearly all industries and sectors. GPM's past successes have been widely covered by leading news and industry publications such as The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron's, Investor's Business Daily, Forbes, and Money. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
